Increased Incidence of Affiliated Conditions and Aging Population
The growing worldwide prevalence of chronic conditions like COPD, congenital cardiac disease, and connective tissue disorders, all of which are secondary risk factors for pulmonary hypertension, are major impetuses. For instance, Centers for Disease Control & Prevention (CDC) reports, heart disease is still a major cause of death worldwide, and it contributes to a large pool of at-risk patients for PAH. The world's population is aging rapidly; the United Nations projects that by 2050, one in six people worldwide will be over age 65. This demographic shift is crucial as the elderly are more susceptible to age-related cardiovascular & pulmonary conditions, thereby increasing the prevalence of PAH & the demand for effective treatments.
Advancements in Diagnostics and Therapeutic Innovation
Advances in diagnostic modalities such as echocardiography, right heart catheterization, and genetic testing enable the earlier and more precise diagnosis of PAH. Additionally, ongoing innovation in drug development, especially the introduction of targeted therapies aimed at different pathophysiological pathways of PAH, is transforming treatment paradigms. For instance, new treatments like the soluble guanylate cyclase (sGC) stimulators and prostacyclin analogues provide better patient outcomes, such as increased exercise capacity and decreased hospitalizations. Such continued R&D, sometimes aided by government as well as private investments for orphan diseases, broadens the therapeutic armamentarium, increasing opportunities for effective treatment as well as driving market growth.
Appearance of Disease-Modifying Therapies
Pulmonary arterial hypertension market is set to undergo dramatic change with the emergence of new disease-modifying treatments that seek to overcome symptom control and attack the underlying pathology. Sotatercept, a first-in-class activin receptor-like kinase (ALK) inhibitor, has exhibited encouraging data in clinical trials, revealing an enormous risk reduction in clinical worsening or death. This is a paradigm shift from vasodilatory strategies alone. The commercial success and market introduction of such new medicines could meaningfully increase the population of patients who can be treated and significantly enhance long-term health outcomes, warranting premium prices and driving high revenue growth as these treatments progress through regulatory approvals and into widespread clinical application.
Untapped Potential in Emerging Economies
Asia-Pacific and Latin America, the emerging economies, offer significant untapped potential for market expansion. These regions have large patient bases, enhancing healthcare infrastructure and growing healthcare spending. Although diagnostic and treatment rates of PAH have been lower in the past versus those in developed nations, increasing awareness campaigns, government actions to increase healthcare accessibility, and higher incidence of lifestyle diseases are driving market growth. With advancing healthcare systems and increasing disposable incomes, there will be higher demand for sophisticated PAH treatments. Companies that strategically enter these markets with localized distribution networks, cost-effective treatment alternatives, and patient education programs can realize enormous revenue streams & secure solid market positions.
The following Key Market Indicators present a comprehensive overview of the social and economic landscape of the selected region, offering critical insights into market-specific trends and developments. These indicators, combined with data from government statistics, industry associations, and corporate sources, form the analytical foundation of NextGen Intelligence Stats' market models.
| Aspects | Details |
Base Year
|
2024 |
Historic Data
|
2021-2023 |
Forecast Period
|
2025-2035 |
Regions & Countries Covered
|
Regions & Countries Covered North America (United States, Canada), Europe (Germany, France, Italy, United Kingdom, Spain, Rest of Europe), Asia Pacific (China, Japan, South Korea, India, Rest of Asia Pacific), Latin America ( |
Companies Profiles
|
|
Segmentation Level Customization
|
|
Company Level Customization
|
|
Country level Data Customization
|
Segmental volume analysis Pricing Analysis of Product Company Market Share |
March 2024: Johnson & Johnson’s Opsynvi, a single tablet combining macitentan (an endothelin receptor antagonist marketed as Opsumit) and tadalafil (a PDE5 inhibitor), was approved by the FDA. The approval relies on the pivotal Phase 3 A DUE trial, in which it was shown that Opsynvi was superior to either monotherapy in lowering pulmonary vascular resistance in adult PAH patients.
March 2024: Merck & Co., Inc. reported FDA approval of Winrevair (sotatercept) to treat pulmonary arterial hypertension. Winrevair is a first-in-class activin receptor-like kinase (ALK) inhibitor, a major step forward as it addresses the root cause of the disease and not just the symptoms. It was approved based on the STELLAR Phase 3 trial, which resulted in significant improvement in clinical worsening events.
February 2025: Lupin Limited and its alliance partner Natco Pharma Limited have received U.S. FDA approval for Natco's Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension. The generic equivalent of Tracleer is approved for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients 3 years of age and above.
March 2024: Sandoz Inc. gained FDA approval for Jubbonti (denosumab-bddz) and Wyost (denosumab-bddz), biosimilars to Prolia and Xgeva, respectively, which are interchangeable. Though not specifically PAH-related, this shows Sandoz's ongoing interest in adding to its pool of biosimilars, which ultimately might include biosimilar versions of PAH treatments when patents run out, thereby boosting market competition and patient availability.
The pulmonary arterial hypertension market is highly competitive, with a combination of mature pharmaceutical giants and new-age biotech companies competing for market share. Players are strategically positioned to increase their product offerings through heavy investment in research and development, especially in new disease-modifying therapies for the underlying disease pathology of PAH, going beyond symptomatic management. Players are increasingly investigating combination treatments to increase efficacy and deliver better outcomes for patients. Mergers and acquisitions, collaborations, and licensing arrangements are common moves used to enhance market presence and pipeline strength. The takeover of prospective drug candidates or firms with a significant emphasis on orphan diseases such as PAH enables industry leaders to readily incorporate new science and enlarge their therapeutic pipelines. Patient-centric strategies, such as designing easy-to-use drug delivery systems & patient support initiatives, are also emerging as key competitive differentiators.
• Johnson & Johnson
• United Therapeutics Corporation
• Bayer AG
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• AbbVie Inc.
• Acceleron Pharma, Inc.
• Arena Pharmaceuticals, Inc.
• Sandoz Inc.
• Viatris Inc.
• GlaxoSmithKline
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.
• Actelion Pharmaceuticals
• Pfizer
• Reata Pharmaceuticals
• Lung Biotechnology
• Liquidia Technologies
• SteadyMed Therapeutics
• Complexa Inc.
• Bellerophon Therapeutics
• Innoven Life Sciences
• Others
Global Pulmonary Arterial Hypertension Market size is anticipated to reach US$ 14,785.47 million by 2035, expanding from US$ 7998.25 million in 2024 and growing steadily at a compound annual growth rate (CAGR) of 5.5%.
Global Pulmonary Arterial Hypertension Market CAGR 5.5% Strategic Growth Forecast 2025–2035
Increased Incidence of Affiliated Conditions and Aging Population, Advancements in Diagnostics and Therapeutic Innovation, Appearance of Disease-Modifying Therapies, Untapped Potential in Emerging Economies
North America is the largest market in the North America Pulmonary Arterial Hypertension Market 31.8% share in 2024.
North America Pulmonary Arterial Hypertension Market share, 2024
Source: NextGen Intelligence Stats and Consulting LLP
North America is the largest market in the North America Pulmonary Arterial Hypertension Market share, 2024 accounting for 31.8% share in 2024. North America has well-established healthcare infrastructure, high investment in research and development, and existence of top pharmaceutical firms. Also, the regions has good awareness of PAH, strong diagnostic facilities, and good reimbursement policies for expensive, specialist therapies.
Asia-Pacific is poised to be the fastest-growing region in the pulmonary arterial hypertension market, projected to grow at a CAGR of 6.8%. This rapid growth is driven by growing aging population, improving healthcare infrastructure, and rising disposable incomes that lead to increased healthcare spending. In addition, rising awareness regarding PAH, especially in the growing economies of China and India, is leading to early diagnosis and wider acceptance of new-age therapies.
1.1. Introduction
1.2. Report Description & Objective
1.3. Assumption And Limitation
2.1. Data Collection
2.2. Primary Research & Secondary Research
2.3. Bottom-Up Approach & Top-Down Approach
2.4. Market Analysis & Size Estimation
2.5. Quality Check & Final Review
3.1. Report Scope
3.2. Executive Summary
4.1. Top Trends To Watch
4.2. Top Strategies Followed By Key Players
4.3. Top Investment Pockets
5.1. Market Definition
5.2. Market Drivers
5.3. Market Restraints & Challenges
5.4. Market Opportunities
6.1. Porter’s Five Forces’ Analysis
6.2. Value Chain Analysis / Supply Chain Analysis
6.3. PESTLE Analysis
6.4. Regulatory Landscape
6.5. Pricing Analysis
7.1. Global Pulmonary Arterial Hypertension Market, By Drug Class
7.2. Global Pulmonary Arterial Hypertension Market Attractiveness, By Drug Class
7.2.1. Endothelin Receptor Antagonists (ERAs)
7.2.2. PDE-5 Inhibitors
7.2.3. Prostacyclin and Prostacyclin Analogs
7.2.4. SGC Stimulators
8.1. Global Pulmonary Arterial Hypertension Market, By Type
8.2. Global Pulmonary Arterial Hypertension Market Attractiveness, By Type
8.2.1. Branded
8.2.2. Generics
9.1. Global Pulmonary Arterial Hypertension Market, By Route of Administration
9.2. Global Pulmonary Arterial Hypertension Market Attractiveness, By Route of Administration
9.2.1. Oral
9.2.2. Intravenous/ subcutaneous
9.2.3. Inhalational
10.1. Global Pulmonary Arterial Hypertension Market, By Distribution Channel
10.2. Global Pulmonary Arterial Hypertension Market Attractiveness, By Distribution Channel
10.2.1. Hospitals
10.2.2. Retail Pharmacies
10.2.3. Online Pharmacies
11.1. Global Pulmonary Arterial Hypertension Market, By Geography
11.2. Global Pulmonary Arterial Hypertension Market Attractiveness, By Geography
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Middle East & Africa
11.2.5. Latin America
12.1. North America Market Overview, By Countries
12.2. North America Market Overview, By Drug Class
12.3. North America Market Overview, By Type
12.4. North America Market Overview, By Route of Administration
12.5. North America Market Overview, By Distribution Channel
12.5.1. United States
12.5.2. Canada
13.1. Europe Market Overview, By Countries
13.2. Europe Market Overview, By Drug Class
13.3. Europe Market Overview, By Type
13.4. Europe Market Overview, By Route of Administration
13.5. Europe Market Overview, By Distribution Channel
13.5.1. Germany
13.5.2. France
13.5.3. UK
13.5.4. Italy
13.5.5. Spain
13.5.6. Rest of Europe
14.1. Asia Pacific Market Overview, By Countries
14.2. Asia Pacific Market Overview, By Drug Class
14.3. Asia Pacific Market Overview, By Type
14.4. Asia Pacific Market Overview, By Route of Administration
14.5. Asia Pacific Market Overview, By Distribution Channel
14.5.1. India
14.5.2. China
14.5.3. Japan
14.5.4. South Korea
14.5.5. Rest of Asia Pacific
15.1. Middle East & Africa Market Overview, By Countries
15.2. Middle East & Africa Market Overview, By Drug Class
15.3. Middle East & Africa Market Overview, By Type
15.4. Middle East & Africa Market Overview, By Route of Administration
15.5. Middle East & Africa Market Overview, By Distribution Channel
15.5.1. GCC
15.5.2. South Africa
15.5.3. Rest of Middle East & Africa
16.1. Latin America Market Overview, By Countries
16.2. Latin America Market Overview, By Drug Class
16.3. Latin America Market Overview, By Type
16.4. Latin America Market Overview, By Route of Administration
16.5. Latin America Market Overview, By Distribution Channel
16.5.1. Brazil
16.5.2. Argentina
16.5.3. Rest of Latin America
17.1. Key Developments
17.1.1. Partnerships, Collaborations, Agreements
17.1.2. Mergers & Acquisitions
17.1.3. New Product Developments
17.1.4. Other Developments
17.2. Company Share Analysis
17.3. Company Profiles
17.3.1. Johnson & Johnson
17.3.1.1. Company Overview
17.3.1.2. Product Overview
17.3.1.3. Financial Insights
17.3.1.4. Recent Developments
17.3.1.5. SWOT Analysis
17.3.2. United Therapeutics Corporation
17.3.3. Bayer AG
17.3.4. Gilead Sciences, Inc.
17.3.5. Merck & Co., Inc.
17.3.6. Novartis AG
17.3.7. AbbVie Inc.
17.3.8. Acceleron Pharma, Inc.
17.3.9. Arena Pharmaceuticals, Inc.
17.3.10. Sandoz Inc.
17.3.11. Viatris Inc.
17.3.12. GlaxoSmithKline
17.3.13. Lupin Pharmaceuticals, Inc.
17.3.14. Sun Pharmaceutical Industries, Inc.
17.3.15. Teva Pharmaceutical Industries Ltd.
17.3.16. Actelion Pharmaceuticals
17.3.17. Pfizer
17.3.18. Reata Pharmaceuticals
17.3.19. Lung Biotechnology
17.3.20. Liquidia Technologies
17.3.21. SteadyMed Therapeutics
17.3.22. Complexa Inc.
17.3.23. Bellerophon Therapeutics
17.3.24. Innoven Life Sciences
Data Collection
Primary Research & Secondary Research
Bottom-Up Approach & Top-Down Approach
Market Analysis & Size Estimation
Quality Check & Final Review
By Drug Class
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
By Type
• Branded
• Generics
By Route of Administration
• Oral
• Intravenous/ subcutaneous
• Inhalational
By Distribution Channel
• Hospitals
• Retail Pharmacies
• Online Pharmacies
© NextGen Intelligence Stats and Consulting LLP All rights reserved.
